Faculty Advisor

Dittami, James P.

Center

University of Massachusetts Medical Center

Abstract

In the last year, an estimated 36.7 million people were living with the Human Immunodeficiency Virus (HIV), with 5,700 new infections occurring daily. Currently, there are 26 FDA approved antiretroviral drugs for the treatment of HIV; however, drug resistance still remains a major problem associated with the current treatments. GS-8374 is a novel protease inhibitor that makes use of a diethyl phosphonate group at the P1 position and has a superior resistance profile when compared to that of current FDA approved inhibitors. For this project three new analogues of GS-8374 were synthesized and tested against the I84V mutant, which confers resistance to most protease inhibitors, of HIV protease.

Publisher

Worcester Polytechnic Institute

Date Accepted

April 2017

Major

Chemistry

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Chemistry and Biochemistry

Project Center

University of Massachusetts Medical Center

Share

COinS